Trial site
Providence Cancer Institute Franz Clinic
- 23running trials
- 11closed trials
The trials here
What the 35 trials at this site are about, from their registry records.
- Conditions
- Lung cancer18 trials
- Head and neck cancer9 trials
- Melanoma8 trials
- Ovarian cancer7 trials
- Colorectal cancer6 trials
- Metastatic breast cancer6 trials
- Cervical cancer5 trials
- Bladder cancer4 trials
- Endometrial cancer4 trials
- Gastric and oesophageal cancer4 trials
- Pancreatic cancer4 trials
- Childhood cancers3 trials
- and 7 more
- Phase
- Phase 312 trials
- Phase 111 trials
- Phase 1/25 trials
- Phase 25 trials
- Phase 2/31 trial
- Status
- Active, not recruiting17 trials
- Completed6 trials
- Recruiting6 trials
- Terminated3 trials
- Withdrawn2 trials
- Suspended1 trial
- Lead sponsor
- Pfizer9 trials
- Seagen, a wholly owned subsidiary of Pfizer5 trials
- Gilead Sciences2 trials
- TScan Therapeutics, Inc.2 trials
- Adaptimmune1 trial
- and 16 more
Running trials
Active, not recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer3 recruiting
- Cervical cancer2 recruiting
- Head and neck cancer2 recruiting
- Metastatic breast cancer2 recruiting
- Ovarian cancer2 recruiting
- Bladder cancer1 recruiting
- Endometrial cancer1 recruiting
- Gastric and oesophageal cancer1 recruiting
- Melanoma1 recruiting
- Pancreatic cancer1 recruiting
Closed trials
Recruiting
Terminated
Recruiting
Completed
Completed
Completed
Terminated
Terminated
Completed
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
Completed
Completed
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
Site data: ClinicalTrials.govUpdated 19 Nov 2026